Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Zenith with Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Indianapolis, IN – Eli Lilly and Company, a venerable pharmaceutical giant, has officially seized the top position in global pharmaceutical…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, concluding fiscal year 2025 as…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
In a groundbreaking development that could revolutionize the treatment of ocular cancers, researchers in China have successfully engineered eye drops…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development stands at a pivotal juncture, grappling with a paradoxical shift in drug modality approvals that signals…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has made a historic leap, claiming the top position in the prestigious Pharma 50 ranking for 2026, a…
Read More
TrumpRx.gov: A Federal Portal’s Ambitions and the Intensifying Scrutiny of Direct-to-Consumer Drug Sales
As of early February, TrumpRx.gov presents a starkly minimalist facade: a stylized Oval Office portrait of the president accompanied by…
Read More
The ‘forever drug’ assumption about GLP-1s may be wrong, according to nference analysis
A paradigm shift in the understanding of GLP-1 receptor agonists, widely recognized as transformative agents in the battle against obesity…
Read MoreYOU MAY HAVE MISSED
